
Almujtaba Ahmed
62 posts




























🚨 Resectable Gastric Cancer | #GI26 CRITICS-II answers a key question What is the best preoperative strategy when adjuvant therapy is omitted? 🧪 Trial design Three fully neoadjuvant approaches compared ➡️ Chemotherapy alone ➡️ Chemotherapy → Chemoradiotherapy ➡️ Chemoradiotherapy alone 🎯 Primary endpoint 1-year event-free survival Activity threshold ≥75% 📊 Key results ✅ CT → CRT: 1-yr EFS 84% | 1-yr OS 89% | pCR 20% ✅ CRT alone: 1-yr EFS 78% | better compliance | lower toxicity ❌ CT alone: 1-yr EFS 68% | lowest survival | higher toxicity 🧠 Clinical interpretation • Chemotherapy alone fails efficacy threshold • Total neoadjuvant therapy gives the best oncologic signal • CRT alone offers a toxicity-compliant alternative • CT → CRT emerges as the preferred backbone for phase III testing and organ-sparing strategies 📌 Take-home message In resectable gastric cancer, treatment intensification before surgery matters. Pure chemo upfront is no longer convincing. #OncoTwitter #MedTwitter #GastricCancer #GI26 @asco @oncoalert @Larvol














